APO-TICAGRELOR 90 MG
TICAGRELOR : 90 MG · DIN 02482630 · APOTEX INC
Health Canada status: MARKETED
What is APO-TICAGRELOR?
APO-TICAGRELOR 90 MG contains TICAGRELOR : 90 MG. It is listed in the Health Canada Drug Product Database under DIN 02482630, held by APOTEX INC, supplied as TABLET for ORAL administration. Health Canada currently lists it as marketed, status dated 14-Dec-2022. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
Product details and regulatory record
| DIN | 02482630 |
|---|---|
| Brand name | APO-TICAGRELOR |
| Generic / active ingredient | TICAGRELOR : 90 MG |
| Manufacturer | APOTEX INC |
| Strength | 90 MG |
| Dosage form | TABLET |
| Route of administration | ORAL |
| Schedule | Prescription |
| ATC code | B01AC24 TICAGRELOR |
| AHFS class | 28:08.08 |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 14-Dec-2022 |
What can be used instead?
Other Canadian products sharing ATC code B01AC24 TICAGRELOR. 12 of 14 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| AG-TICAGRELOR | 60 MG | TABLET | ANGITA PHARMA INC. | MARKETED | DIN 02537184 |
| AG-TICAGRELOR | 90 MG | TABLET | ANGITA PHARMA INC. | MARKETED | DIN 02537192 |
| APO-TICAGRELOR | 60 MG | TABLET | APOTEX INC | MARKETED | DIN 02482622 |
| BRILINTA | 60 MG | TABLET | ASTRAZENECA CANADA INC | MARKETED | DIN 02455005 |
| BRILINTA | 90 MG | TABLET | ASTRAZENECA CANADA INC | MARKETED | DIN 02368544 |
| JAMP TICAGRELOR | 60 MG | TABLET | JAMP PHARMA CORPORATION | MARKETED | DIN 02531798 |
| JAMP TICAGRELOR | 90 MG | TABLET | JAMP PHARMA CORPORATION | MARKETED | DIN 02531801 |
| M-TICAGRELOR | 60 MG | TABLET | MANTRA PHARMA INC | MARKETED | DIN 02529750 |
| M-TICAGRELOR | 90 MG | TABLET | MANTRA PHARMA INC | MARKETED | DIN 02529769 |
| TARO-TICAGRELOR | 60 MG | TABLET | TARO PHARMACEUTICALS INC | MARKETED | DIN 02492571 |
Who else supplies TICAGRELOR worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. TICAGRELOR appears in 424 registered pack listings across 15 markets, published on 12 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.